Cretostimogene Grenadenorepvec (NCT06567743)

Name: Cretostimogene Grenadenorepvec trial for High-Risk Non-Muscle-Invasive Bladder Cancer (NCT06567743)
Uploaded: 2026-10-31T19:54:50.782Z
Duration: 1 min 10 s
Description: Cretostimogene Grenadenorepvec trial for High-Risk Non-Muscle-Invasive Bladder Cancer (NCT06567743). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06567743.

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC: a one-minute explainerNCT065677431 min

Cretostimogene Grenadenorepvec trial for High-Risk Non-Muscle-Invasive Bladder Cancer (NCT06567743). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with high-risk, high-grade bladder cancer that has not invaded muscle. Separate groups include patients with no prior BCG and those previously treated with BCG.

The idea: cretostimogene is a modified virus placed inside the bladder, intended to destroy tumor cells and trigger immunity. Groups test delivery methods or, after prior BCG, schedules combining it with gemcitabine. Treatment begins weekly; further courses depend on disease findings.

This phase 2 study plans 325 patients. CG Oncology sponsors it; 75 US sites are recruiting.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.